Eyepoint Says Topline Results From Lucia Phase 3 Trial Of Duravyu (Vorolanib Intravitreal Insert) For Wet Age-Related Macular Degeneration Did Not Achieve The Primary Endpoint
– LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement –– Key secondary endpoints in LUCIA were
Eyepoint's new eye medicine did not work as well as hoped in testing. When a medicine fails its main test, investors watch to see what the company does next.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.